Industry News

Neovasc Inc. today announced financial results for the quarter ended June 30, 2016. "Activities to increase the rate of enrolment of patients in the Tiara clinical program, including adding new centres, introducing the 40 mm Tiara and refining inclusion criteria are resulting in an increased number of implantations. There have now been 19 patients treated with Tiara and we continue to be encouraged by the early results from these cases, "..."/>
Neovasc Reports Second Quarter Results for 2016
Innovus Pharmaceuticals, Inc., announced today that the Company turned cash flow positive with over $256,000 in cash provided by operations which is ahead of its projected timelines, due to higher revenues from the sale of its Beyond Human and Innovus Pharma products. "Becoming operationally cash flow positive from the second quarter and ahead of the timeline projected is a major financial achievement for the Company and a big..."/>
Innovus Pharma Turns Cash Flow Positive With Over $1 Million in Revenues for the Second Quarter 2016
Meridian Bioscience, has received clearance from the China Food and Drug Administration for its LeadCare ® II Blood Lead Testing System. The system is small, portable, and produces a quantitative blood lead level in only three minutes, using just two drops of blood. This system is used in thousands of pediatric and primary care settings in the United States to help doctors diagnose lead exposure..."/>
Magellan Diagnostics Receives CFDA Clearance for LeadCare II in China
Allergan's Actavis generic division last week, Teva Pharmaceutical Industries Ltd. paid Allergan $33.4 billion in cash and a little more than 100 million Teva shares. Now comes Allergan's report to the US Securities and Exchange Commission on its holdings in Teva. Yesterday's report shows that Allergan own 9.9% of Teva's share capital, thereby becoming the largest shareholder in Teva."/>
Allergan becomes largest shareholder in Teva [Globes, Tel Aviv, Israel]
MGT Capital Investments, Inc. has announced the release of Demonsaw 3.0, a secure and decentralized x-platform information-sharing application with end-to-end encryption and no client P2P. Demonsaw 3.0 inherits the security and anonymity principles from Demonsaw 2.0 but makes many advances in network communication, speed, security, anonymity and extensibility. The entire application was re-written from the ground-up based on user..."/>
MGT Capital Investments Releases Demonsaw 3.0
Press Ganey Holdings, Inc. by EQT Partners AB. On August 9, 2016, the two companies announced the signing of a definitive merger agreement pursuant to which EQT Partners will acquire Press Ganey. Under the terms of the agreement, Press Ganey shareholders will receive $40.50 for each share of Press Ganey common stock."/>
Robbins Arroyo LLP: Acquisition of Press Ganey Holdings, Inc. (PGND) by EQT Partners AB May Not Be in Shareholders' Best Interests
Meridian Bioscience, Inc. today announced Magellan Diagnostics, a business unit of Meridian Bioscience, has received clearance from the China Food and Drug Administration for its LeadCare II Blood Lead Testing System. The system is small, portable, and produces a quantitative blood lead level in only three minutes, using just two drops of blood. This system is used in thousands of pediatric and primary care settings in the United States to help doctors..."/>
Magellan Diagnostics Receives CFDA Clearance for LeadCare® II in China
Caduceus Software Systems Corp.,: Caduceus Software Systems Corp. would like to inform its valued shareholders that the Company has accepted, cancelled, and returned to treasury 75,000,000 restricted common shares. Our OTC Markets Company Profile Page will be updated once the cancellation has been confirmed. Reduction of the common shares by 75,000,000 leaves our New Outstanding and Issued share count at 719,200,000. Out of these shares, 629,600,000 are..."/>
Caduceus Software Systems Corp Announces Reduction to Outstanding Capital Shares and Corporate Update
Coherus BioSciences, Inc., today announced submission of the biologics license application for CHS-1701, a pegfilgrastim biosimilar candidate, to U.S. FDA under the 351 pathway.. The BLA submission is supported by similarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies comparing CHS-1701 and Neulasta."/>
Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
Press Ganey announced that it is being acquired by the private equity firm, EQT Equity for $40.50 in cash per share. According to Carl Stine, who is a partner at Wolf Popper LLP, "With insiders owning a majority of the shares, it is not surprising that the management of Press Ganey, which will undoubtedly team up with EQT, has decided to sell the company at such a low price." The offer price is only a premium of less than 1% from yesterday's..."/>
Wolf Popper LLP Investigates Buyout of Press Ganey Holdings, Inc. by EQT Equity
PetVivo Holdings, Inc., an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced an investment research report on the Company. The initiation of coverage report provides a comprehensive overview of the Company and its industry, along with a company valuation..."/>
Marble Arch Research Inc. Initiates Research Coverage of Petvivo Holdings, Inc.
Aethlon Medical, Inc., today announced that it will host its First Quarter Fiscal 2017 investor conference call and webcast on Thursday, August 11, 2016 at 4:30 p.m. Eastern Time. The call and webcast will follow the release of fiscal 2017 first quarter results. A recorded version of the call will be available approximately two hours after the call at the Investor Relations portion of the company's website,"/>
Aethlon Medical To Host First Quarter Fiscal 2017 Investor Call On August 11, 2016
Akers Biosciences, Inc.,, a developer of rapid health information technologies, will hold a conference call on Thursday, August 11, 2016 at 09:00 a.m. Eastern Time to discuss its earnings for the second quarter ended June 30, 2016, which will be published earlier that day. Management will be available during a question-and-answer session. To participate in the call from within the U.S., please dial 1-888-417-8465 approximately 10 minutes prior to the..."/>
Akers Biosciences Announces Conference Call to Discuss Q2 2016 Earnings
Humana Inc., one of the country’ s leading health and well-being companies, announced today it has added eMindful’ s live, online mindfulness training programs to its growing resource of wellness solutions available to employers. This Smart News Release features multimedia. View the full release here:"/>
Humana Adds Mindfulness Programs to Wellness Solutions Available to Employers
Sorrento Therapeutics, Inc.' s Scintilla Pharmaceuticals, Inc. subsidiary has entered into a binding term sheet to acquire US-based pain drug developer Scilex Pharmaceuticals, Inc., the company said. In consideration for the acquisition, Sxilex equity holders will receive up toUSD 70 min stock of Scintilla, following the next equity financing of Scintilla. Scintilla's lead program is resiniferatoxin for the treatment of intractable cancer..."/>
Scintilla Pharmaceuticals to Acquire Pain Drug Developer Scilex for Up to USD 70m
Trovagene, Inc., a developer of circulating tumor DNA molecular diagnostics, is scheduled to attend the 2016 Avondale Partners Healthcare 1-1 Conference on Wednesday, August 10, 2016 at the Boston Harbor Hotel, in Boston, Massachusetts. Bill Welch, Chief Executive Officer of Trovagene, will be attending the conference which consists of one-on-one investor meetings as well as small group meetings. No formal presentations are being made."/>
Trovagene to Attend the 2016 Avondale Partners Healthcare 1-1 Conference
Medovex Corp., a developer of medical technology products, today announced the successful completion of a $1,150,000 financing transaction led by an investment from Sorrento Therapeutics, Inc.. On August 5, 2016, MedoveX Corporation entered into a unit purchase agreement with selected accredited investors. Pursuant to the terms of the agreement, the Company sold 4.6 units for gross proceeds of $1,150,000. Each unit had a purchase price of $250,000 and..."/>
Medovex Corp. Completes Financing Led by Sorrento Therapeutics, Inc.
ImpediMed Limited, a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced that the U.S. Food and Drug Administration has issued new guidance surrounding digital health. "These guidance documents could significantly impact those companies already in, or about to enter, the digital health space," said Richard Carreon, Managing Director and CEO of..."/>
FDA Releases Important Information Focused on Digital Health
pSivida Corp.;, a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that its utilization study of its new, proprietary 27- gauge inserter for Medidur for posterior uveitis has met its primary endpoint. In the study, 66 percent of injections using the new 27- gauge inserter achieved a satisfactory rating of“ Routine,”“ Easy” or“ Very Easy” while only 46 percent of injections utilizing the earlier,..."/>
Primary Endpoint Met in pSivida’s Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle
Lupin Ltd, India's third largest drug maker, recorded a 55% growth in its consolidated net profit for the first quarter ended 30 June, beating analyst estimates on the back of strong US sales. Net profit rose to Rs.882 crore in the April-June period from Rs.568.6 crore a year ago, the company said in a statement to the BSE on Tuesday. Total revenues grew 41% to Rs.4, 439 crore, the company said."/>
Lupin posts record net profit of Rs882 crore in Q1 FY17 [Mint, New Delhi]
Godrej Properties Ltd on Tuesday posted a 9.19% increase in its net profit to Rs.43.5 crore in the June quarter as compared to the same period last fiscal, on account of improved sales. In a filing to the Bombay Stock Exchange, the company said its total income has jumped by around 52.5% to Rs.303.83 crore during the reporting quarter as against the same period last financial year, mainly due to sales coming from its commercial project at Bandra Kurla..."/>
Godrej Properties Q1 net profit up 9% at Rs 43.5 crore [Mint, New Delhi]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary667 Articles
Information Technology610 Articles
Financials512 Articles
Health Care358 Articles
Industrials354 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at